BACKGROUND/AIMS: In this study, it was reappraised the outcomes of total pancreatectomy (TP), retrospectively analyzing the safety of the procedures and factors associated with long-term survival. METHODOLOGY: Thirty-six consecutive patients underwent TP for pancreas disease at Kobe University Hospital. The outcomes of TP were evaluated, analyzing operation-related results (mortality, morbidity, survival and long-term outcomes) and oncological aspects. RESULTS: Postoperative morbidity was 39% (14/36) and severe complications were anastomotic leakage (n=3) and liver necrosis (n=1). In benign disease, 5-year survival was 50%, while 5-year survival in malignant disease was 22%. Postoperative glycosylated hemoglobin A1c (HbA1c) level was 7.8 +/- 1.2% at 6 months and 7.8 +/- 1.5% at 12 months after TP, respectively. CONCLUSION: TP is safely performed and the treatment option for selectively limited pancreatic cancer and intraductal papillary mucinous neoplasm of the pancreas (IPMN), when the patient condition permits and offers a chance of cure, although careful long-term medical care and follow-up are essential.
BACKGROUND/AIMS: In this study, it was reappraised the outcomes of total pancreatectomy (TP), retrospectively analyzing the safety of the procedures and factors associated with long-term survival. METHODOLOGY: Thirty-six consecutive patients underwent TP for pancreas disease at Kobe University Hospital. The outcomes of TP were evaluated, analyzing operation-related results (mortality, morbidity, survival and long-term outcomes) and oncological aspects. RESULTS: Postoperative morbidity was 39% (14/36) and severe complications were anastomotic leakage (n=3) and liver necrosis (n=1). In benign disease, 5-year survival was 50%, while 5-year survival in malignant disease was 22%. Postoperative glycosylated hemoglobin A1c (HbA1c) level was 7.8 +/- 1.2% at 6 months and 7.8 +/- 1.5% at 12 months after TP, respectively. CONCLUSION:TP is safely performed and the treatment option for selectively limited pancreatic cancer and intraductal papillary mucinous neoplasm of the pancreas (IPMN), when the patient condition permits and offers a chance of cure, although careful long-term medical care and follow-up are essential.
Authors: Neil H Bhayani; Laura M Enomoto; Jennifer L Miller; Gail Ortenzi; Jussuf T Kaifi; Eric T Kimchi; Kevin F Staveley-O'Carroll; Niraj J Gusani Journal: HPB (Oxford) Date: 2013-08-29 Impact factor: 3.647
Authors: Reza Fazlalizadeh; Zhobin Moghadamyeghaneh; Aram N Demirjian; David K Imagawa; Clarence E Foster; Jonathan R Lakey; Michael J Stamos; Hirohito Ichii Journal: World J Transplant Date: 2016-03-24
Authors: Jin He; John L Cameron; Nita Ahuja; Martin A Makary; Kenzo Hirose; Michael A Choti; Richard D Schulick; Ralph H Hruban; Timothy M Pawlik; Christopher L Wolfgang Journal: J Am Coll Surg Date: 2013-02-06 Impact factor: 6.113
Authors: Lianne Scholten; Anouk Ej Latenstein; Cora M Aalfs; Marco J Bruno; Olivier R Busch; Bert A Bonsing; Bas Groot Koerkamp; I Quintus Molenaar; Dirk T Ubbink; Jeanin E van Hooft; Paul Fockens; Jolanda Glas; J Hans DeVries; Marc G Besselink Journal: United European Gastroenterol J Date: 2020-07-23 Impact factor: 4.623
Authors: L Scholten; T F Stoop; M Del Chiaro; O R Busch; C van Eijck; I Q Molenaar; J H de Vries; M G Besselink Journal: Br J Surg Date: 2019-09-10 Impact factor: 6.939